Interventions for Tuberculosis Control and Elimination 2002

871. Pamra SP, Mathur GP. Effects of chemoprophylaxis on minimal pulmonary
tuberculosis lesions of doubtful activity.
593-602.
Bull World Health Organ 1971; 45:
872. Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid
prophylaxis in mental institutions. Am Rev Respir Dis 1963; 88: 161-75.
873. Comstock GW. Isoniazid prophylaxis in an undeveloped area. Am Rev Respir
Dis 1962; 86: 810-22.
874. Mount FW, Ferebee SH. The effect of isoniazid prophylaxis on tuberculosis
morbidity among household contacts of previously known cases of tuberculosis.
Am Rev Respir Dis 1962; 85: 821-7.
875. Horwitz O, Payne PG, Wilbek E. Epidemiological basis of tuberculosis eradication.
509-29.
4. The isoniazid trial in Greenland. Bull World Health Organ 1966; 35:
876. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of communitywide
isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95: 935-43.
877. Groth-Petersen E, Østergaard F. Mass chemoprophylaxis of tuberculosis. The
acceptability and untoward side effects of isoniazid in a control study in
Greenland. Am Rev Respir Dis 1960; 81: 643-52.
878. Veening GJJ. Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis
after recent tuberculin conversion in young adults.
1968; 41: 169-71.
Bull Int Union Tuberc
879. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic
use of isoniazid among household contacts.
85: 490-521.
Am Rev Respir Dis 1962;
880. Egsmose T, Ang’Awa JOW, Poti SJ. The use of isoniazid among household
contacts of open cases of pulmonary tuberculosis.
1965; 33: 419-33.
Bull World Health Organ
881. Bush OB, Jr, Sugimoto M, Fuji Y, Brown FA, Jr. Isoniazid prophylaxis in contacts
of persons with known tuberculosis.
1965; 92: 732-40.
Second report. Am Rev Respir Dis
882. Goletti D, Weissman D, Jackson RW, Collins F, Kinter A, Fauci AS. The in vitro
induction of human immunodeficiency virus (HIV) replication in purified protein
derivative-positive HIV-infected persons by recall antigen response to Mycobacterium
tuberculosis is the result of a balance of the effects of endogenous interleukin-2
and proinflammatory cytokines. J Infect Dis 1998; 177: 1332-8.
883. Del Amo J, Malin AS, Pozniak A, De Cock KM. Does tuberculosis accelerate
the progression of HIV disease? Evidence from basic science and epidemiology.
AIDS 1999; 13: 1151-8.
884. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD, Jr. Effect of isoniazid prophylaxis
on incidence of active tuberculosis and progression of HIV infection.
Lancet 1993; 342: 268-72.
228